

IN THE CLAIMS

Cancel claims 1-21 without prejudice.

Add claims 22-25 which follow:

Claim 22: A method for screening for possibility of a disorder characterized by expression of a BAGE tumor rejection antigen precursor encoded by the nucleotide sequence of SEQ ID NO: 1, or comprising the amino acid sequence of SEQ ID NO: 2, comprising contacting a sample with an agent specific for said BAGE tumor rejection antigen precursor, and determining binding between said agent and said BAGE tumor rejection antigen precursor as a determination of possibility of said disorder.

Claim 23: The method of claim 22, wherein said agent is an antibody.

Claim 24: The method of claim 22, wherein said disorder is cancer

Claim 25: The method of claim 22, wherein said cancer is melanoma.


REMARKS

Entry of the amendment is requested.

Claims 22-25 represent subject matter that was withdrawn from consideration following a restriction requirement in the parent application.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.



Norman D. Hanson
Reg. No. 30,986

666 Fifth Avenue
New York, New York 10103
(212) 318-3000